Recently, at the 2020 China Corporate Social Responsibility Cloud Summit hosted by Xinhuanet.com and co-sponsored by the China Enterprise Reform and Development Research Association, Akcome Group (hereinafter referred to as “Aikang”) won the “2020 Chinese Enterprise” for its outstanding performance during the anti-epidemic period. Outstanding Corporate Social Responsibility Award".
Fulfilling corporate social responsibility is a mission that needs to be undertaken in the development of enterprises. Since the outbreak of the epidemic in early 2020, as a leading company in the health examination and health management industry, Akcome has been using its own methods to assume the responsibilities of social medical institutions and help prevent the epidemic. control.
From rushing to the front line of Wuhan to opening a free "New Coronavirus Prevention and Control Expert Consultation Hotline", from contributing to the new crown vaccine to supporting nucleic acid testing for all employees in Beijing, Dalian nucleic acid testing, and Shijiazhuang nucleic acid testing, from participating in local epidemic prevention and control to taking over Air China crew members Focusing on the emergency support work, "Ikang people" are everywhere in epidemic prevention and control.
Nucleic acid testing is an important starting point for epidemic prevention and control.
While actively supporting the frontline of the anti-epidemic, Akcome also contributes its own efforts to help all localities achieve "should inspections".
Currently, iKang has opened nucleic acid testing and sampling services in 48 cities across the country.
It is particularly worth mentioning that, in order to make the people safer and have no worries about nucleic acid testing, Akcome racked their brains to launch a special "drive-through" nucleic acid testing service, allowing customers to complete nucleic acid testing in the car, which is safe and convenient .
Except for Beijing, the drive-through inspection services have already been implemented in cities such as Shanghai, Hangzhou, Changzhou, and Guiyang.
Recently, Akcome has carried out a comprehensive deployment of nucleic acid testing, calling on its medical examination sites to do the training and preparation of relevant sampling personnel, increase sampling points and sampling personnel according to local conditions, expand the number of open appointments, and extend the sampling time. The testing needs of citizens.
As a health management company, Akcome is full of social responsibility and sustainability, and truly cares about the lives of customers.
Zhang Ligang, the founder, chairman and CEO of Akcome Group, once said, “If customers choose to entrust their lives to us, we are obligated to assume the responsibility of protecting their lives and health.” Since its establishment in 2004, Akcome has always adhered to the principle of “customer first”. , The value of "getting trust with quality", and empowering health management with innovative technology, and better fulfilling social responsibilities.
In the difficult 2020, iKang is dedicated to fighting the epidemic on the one hand, and on the other hand, it uses artificial intelligence, genetic testing and big data technology to further drive the reform of the medical service model.
Last year, Akcome Group had two major milestones in the application of genetic testing and artificial intelligence.
The first is the product service of Nuohui Changweiqing introduced by iKang.
Chang Weiqing is a multi-target stool FIT-DNA detection product developed based on the characteristics of the Chinese population's genome.
In the past four years, as a health consulting project, more than 200,000 people have used this technology for early screening for bowel cancer on the iKang platform.
The second is the Airdoc artificial intelligence retinal imaging technology introduced by iKang. Through a fundus photo, not only the risk of fundus diseases and chronic diseases can be checked, but also brain tumors can be found.
Airdoc's fundus image-assisted diagnosis software for diabetic retinopathy was approved for listing on August 7, 2020, becoming the first fundus artificial intelligence-assisted diagnosis software approved for marketing in China.
In the past two years or so, as a health consultation project, more than 1.5 million people have selected this technology for examination during iKang's physical examination.
As a leading health management group in China, Akcome Group not only takes as its mission to improve the health and quality of life of the Chinese people, but also insists on devoting itself to public welfare undertakings, actively giving back to the society, fulfilling the social responsibility of an excellent company, and creating a "Social atmosphere has contributed to the construction of "Healthy China".